DNLI
Price
$17.15
Change
-$0.37 (-2.11%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
2.57B
109 days until earnings call
Intraday BUY SELL Signals
NTRB
Price
$5.63
Change
-$0.23 (-3.92%)
Updated
Nov 13, 04:58 PM (EDT)
Capitalization
70.53M
18 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs NTRB

Header iconDNLI vs NTRB Comparison
Open Charts DNLI vs NTRBBanner chart's image
Denali Therapeutics
Price$17.15
Change-$0.37 (-2.11%)
Volume$29.05K
Capitalization2.57B
Nutriband
Price$5.63
Change-$0.23 (-3.92%)
Volume$763
Capitalization70.53M
DNLI vs NTRB Comparison Chart in %
DNLI
Daily Signal:
Gain/Loss:
NTRB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNLI vs. NTRB commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and NTRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (DNLI: $17.52 vs. NTRB: $5.86)
Brand notoriety: DNLI and NTRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 104% vs. NTRB: 45%
Market capitalization -- DNLI: $2.52B vs. NTRB: $67.65M
DNLI [@Biotechnology] is valued at $2.52B. NTRB’s [@Biotechnology] market capitalization is $67.65M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileNTRB’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • NTRB’s FA Score: 0 green, 5 red.
According to our system of comparison, NTRB is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while NTRB’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 4 bearish.
  • NTRB’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than NTRB.

Price Growth

DNLI (@Biotechnology) experienced а +17.66% price change this week, while NTRB (@Biotechnology) price change was -1.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

NTRB is expected to report earnings on Dec 01, 2025.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.57B) has a higher market cap than NTRB($70.5M). NTRB YTD gains are higher at: 24.416 vs. DNLI (-14.033). NTRB has higher annual earnings (EBITDA): -9.99M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. NTRB (7M). NTRB has less debt than DNLI: NTRB (270K) vs DNLI (46.6M). NTRB has higher revenues than DNLI: NTRB (2.58M) vs DNLI (0).
DNLINTRBDNLI / NTRB
Capitalization2.57B70.5M3,645%
EBITDA-521.52M-9.99M5,221%
Gain YTD-14.03324.416-57%
P/E RatioN/AN/A-
Revenue02.58M-
Total Cash899M7M12,852%
Total Debt46.6M270K17,259%
FUNDAMENTALS RATINGS
DNLI vs NTRB: Fundamental Ratings
DNLI
NTRB
OUTLOOK RATING
1..100
7984
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4762
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
5017

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTRB's Valuation (48) in the null industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that NTRB’s stock grew somewhat faster than DNLI’s over the last 12 months.

NTRB's Profit vs Risk Rating (100) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (96) in the Biotechnology industry is in the same range as NTRB (100) in the null industry. This means that DNLI’s stock grew similarly to NTRB’s over the last 12 months.

DNLI's Price Growth Rating (47) in the Biotechnology industry is in the same range as NTRB (62) in the null industry. This means that DNLI’s stock grew similarly to NTRB’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as NTRB (100) in the null industry. This means that DNLI’s stock grew similarly to NTRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLINTRB
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
75%
N/A
Declines
ODDS (%)
Bearish Trend 8 days ago
82%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
NTRB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MTGRF0.28N/A
N/A
Mount Gibson Iron Ltd.
VLCJF0.14N/A
N/A
Velocity Minerals Ltd.
CHEOF180.56N/A
N/A
CochLear Ltd.
ORPEF14.22N/A
N/A
Orpea ACT
HLRD420.00N/A
N/A
Hilliard Corp.

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-0.34%
NRIX - DNLI
58%
Loosely correlated
-5.37%
RGNX - DNLI
55%
Loosely correlated
+0.43%
OCUL - DNLI
54%
Loosely correlated
+2.41%
BEAM - DNLI
54%
Loosely correlated
-2.71%
SYRE - DNLI
53%
Loosely correlated
+0.34%
More

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and ABSI have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and ABSI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-3.78%
ABSI - NTRB
31%
Poorly correlated
-1.45%
VRAX - NTRB
31%
Poorly correlated
-1.15%
DNLI - NTRB
29%
Poorly correlated
-0.34%
SONN - NTRB
29%
Poorly correlated
+3.48%
IMCR - NTRB
28%
Poorly correlated
+0.26%
More